Altering brow contour with botulinum toxin

Facial Plastic Surgery Clinics of North America

Volumn 11, Issue 4, 2003, Pages 457-464

  Chen, Achih H ^a   Frankel, Andrew S ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; IODIPINE;

ANATOMY; ARTICLE; DRUG MECHANISM; DRUG PACKAGING; DRUG STORAGE; ECTROPION; ESTHETICS; EXTRAOCULAR MUSCLE; EYEBROW; HUMAN; PTOSIS; SURGICAL TECHNIQUE;

EID: 0345865334     PISSN: 10647406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1064-7406(03)00072-5     Document Type: Review

References (26)

1. Savino PJ, Mause M. Botulinum toxin therapy. Neurol Clin 1991;9:205-24.
2. Simpson LL. The origin, structure, and pharmalogical activity of botulinum toxin. Pharmacol Rev 1981;33: 155-88.
3. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.
4. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000;43: 249-59.
5. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973;12:924.
6. Brin MF, Fahn S, Moskowitz CB, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2: 237-54.
7. Brin MF, Fahn S, Moskowitz CB, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol 1988;50: 599-608.
8. Blitzer A, Brin W. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991;100:85-90.
9. Clark RP, Berris CE. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 1989;84:353.
10. Carruthers J, Carruthers A. Treatment of glabellar frown lines with C botulinum exotoxin. J Dermatol Surg Oncol 1992;18:17-21.
11. Frankel AS, Kamer FM. Chemical brow lift. Arch Otolaryngol Head Neck Surg 1998;124:321-3.
12. Huang W. Browlift with botulinum toxin. Dermatol Surg 2000;26:55-60.
13. Lowe NJ. Botulinum toxin A for facial rejuvenation. Dermatol Surg 1998;24:1216-8.
14. Schantz EJ, Johnson EA. Dose standardization of botulinum toxin. Lancet 1990;335:421.
15. Carruthers A, Carruthers J. Toxins 99. New information about the botulinum neurotoxins. Dermatol Surg 2000; 26:174.
16. Brashear A, Lew W, Dystra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A responsive cervical dystonia. Neurology 1999;53: 1439-46.
17. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A resistant cervical dystonia. Neurology 1999;53:1431-8.
18. Goschel J, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997; 147:96-102.
19. Bowman EJ. Preparation and assay of the international standards for Clostridium botulinum types A, B, C, D, and E antitoxins. Bull World Health Organ 1963;29: 219-60.
20. Arron SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biologic weapon: mental and public health management. JAMA 2001;285:1059-70.
21. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg 1998;24:1179-80.
22. Package Insert for Botox. Irvine, California: Allergan Inc.; 2003.
23. Edelson C, Shorr N, et al. Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998;24:1208-12.
24. Frankel AS. Botox for rejuvenation of the periorbital region. Facial Plast Surg 1999;15:255-62.
25. Daniel RK, Landon B. Endoscopic forhead lift. Anatomic basis. Aesthet Surg J 1997;17:97-104.
26. Matarasso S. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg 1998; 24:1249-54.